Literature DB >> 23257350

Pulmonary hypertension as a prognostic indicator at the initial evaluation in idiopathic pulmonary fibrosis.

Motohiro Kimura1, Hiroyuki Taniguchi, Yasuhiro Kondoh, Tomoki Kimura, Kensuke Kataoka, Osamu Nishiyama, Hiromichi Aso, Koji Sakamoto, Yoshinori Hasegawa.   

Abstract

BACKGROUND: The impact of pulmonary hypertension (PH) on survival has been demonstrated in severe cases with idiopathic pulmonary fibrosis (IPF) who were referred for transplantation. However, whether PH is a predictor of survival remains unclear in milder cases.
OBJECTIVES: To evaluate the survival impact of pulmonary artery pressure measured during the initial evaluation in patients with IPF.
METHODS: We retrospectively analyzed the initial evaluation data of 101 consecutive IPF patients undergoing right heart catheterization. Patients evaluated with supplemental oxygen were excluded. Predictors of 5-year survival were analyzed using the Cox proportional model.
RESULTS: The mean forced vital capacity (FVC) % predicted, diffusing capacity of the lung for carbon monoxide (DLCO) % predicted, and mean pulmonary artery pressure (MPAP) were 70.2 ± 20.1%, 47.9 ± 19.5%, and 19.2 ± 6.5 mm Hg, respectively. A univariate Cox proportional hazard model showed that the body mass index, %FVC, %DLCO, baseline PaO2, modified Medical Research Council score, 6-min walk distance, and lowest SpO2 of the 6-min walk test were significantly predictive of survival. The MPAP and pulmonary vascular resistance of right heart catheterization were also significant. With stepwise, multivariate Cox proportional analysis, MPAP (HR = 1.064; 95% CI 1.015-1.116, p = 0.010) and %FVC (HR = 0.965, 95% CI 0.949-0.982, p < 0.001) were independent determinants of survival. Analysis of the receiver operating curve revealed MPAP >20 mm Hg to be optimal for predicting the prognosis.
CONCLUSIONS: Higher MPAP and lower %FVC at the initial evaluation were significant independent prognostic factors of IPF. The current results suggested the importance of the initial evaluation of PH for patients with IPF.
Copyright © 2012 S. Karger AG, Basel.

Entities:  

Mesh:

Year:  2012        PMID: 23257350     DOI: 10.1159/000345221

Source DB:  PubMed          Journal:  Respiration        ISSN: 0025-7931            Impact factor:   3.580


  49 in total

1.  Survival in pulmonary hypertension due to chronic lung disease: Influence of low diffusion capacity of the lungs for carbon monoxide.

Authors:  Lauren Rose; Kurt W Prins; Stephen L Archer; Marc Pritzker; E Kenneth Weir; Jeffrey R Misialek; Thenappan Thenappan
Journal:  J Heart Lung Transplant       Date:  2018-09-14       Impact factor: 10.247

2.  Staging and outcome in acute exacerbation of idiopathic pulmonary fibrosis: are all limits and determinants under control?

Authors:  Antonio M Esquinas; Alejandro Ubeda Iglesias; Angela Reina González
Journal:  Lung       Date:  2014-10-14       Impact factor: 2.584

3.  Influence of pulmonary hypertension on survival in advanced lung disease.

Authors:  Don Hayes; Sylvester M Black; Joseph D Tobias; Heidi M Mansour; Bryan A Whitson
Journal:  Lung       Date:  2015-02-18       Impact factor: 2.584

4.  Challenges in Pulmonary Hypertension: Controversies in Treating the Tip of the Iceberg. A Joint National Institutes of Health Clinical Center and Pulmonary Hypertension Association Symposium Report.

Authors:  Jason M Elinoff; Richa Agarwal; Christopher F Barnett; Raymond L Benza; Michael J Cuttica; Ahmed M Gharib; Michael P Gray; Paul M Hassoun; Anna R Hemnes; Marc Humbert; Todd M Kolb; Tim Lahm; Jane A Leopold; Stephen C Mathai; Vallerie V McLaughlin; Ioana R Preston; Erika B Rosenzweig; Oksana A Shlobin; Virginia D Steen; Roham T Zamanian; Michael A Solomon
Journal:  Am J Respir Crit Care Med       Date:  2018-07-15       Impact factor: 21.405

5.  Pulmonary hypertension in patients with interstitial pneumonia with autoimmune features.

Authors:  Bashar N Alzghoul; Robert Hamburger; Thomas Lewandowski; Brandon Janssen; Daniel Grey; Wei Xue; Ali Ataya; Hassan Alnuaimat; Diana C Gomez-Manjarres; Divya Patel; Raju Reddy
Journal:  Pulm Circ       Date:  2020-12-07       Impact factor: 3.017

Review 6.  Pulmonary hypertension associated with lung diseases and hypoxemia.

Authors:  Michael J Cuttica
Journal:  Heart Fail Rev       Date:  2016-05       Impact factor: 4.214

7.  Pulmonary Vascular and Right Ventricular Burden During Exercise in Interstitial Lung Disease.

Authors:  Rudolf K F Oliveira; Aaron B Waxman; Paul J Hoover; Paul F Dellaripa; David M Systrom
Journal:  Chest       Date:  2020-03-12       Impact factor: 9.410

8.  Heterogeneous gene expression signatures correspond to distinct lung pathologies and biomarkers of disease severity in idiopathic pulmonary fibrosis.

Authors:  Daryle J DePianto; Sanjay Chandriani; Alexander R Abbas; Guiquan Jia; Elsa N N'Diaye; Patrick Caplazi; Steven E Kauder; Sabyasachi Biswas; Satyajit K Karnik; Connie Ha; Zora Modrusan; Michael A Matthay; Jasleen Kukreja; Harold R Collard; Jackson G Egen; Paul J Wolters; Joseph R Arron
Journal:  Thorax       Date:  2014-09-12       Impact factor: 9.139

9.  Endothelial HIF signaling regulates pulmonary fibrosis-associated pulmonary hypertension.

Authors:  Andrew J Bryant; Ryan P Carrick; Melinda E McConaha; Brittany R Jones; Sheila D Shay; Christy S Moore; Thomas R Blackwell; Santhi Gladson; Niki L Penner; Ankita Burman; Harikrishna Tanjore; Anna R Hemnes; Ayub K Karwandyar; Vasiliy V Polosukhin; Megha A Talati; Hui-Jia Dong; Linda A Gleaves; Erica J Carrier; Christa Gaskill; Edward W Scott; Susan M Majka; Joshua P Fessel; Volker H Haase; James D West; Timothy S Blackwell; William E Lawson
Journal:  Am J Physiol Lung Cell Mol Physiol       Date:  2015-12-04       Impact factor: 5.464

10.  Prognostic value of pre-transplant mean pulmonary arterial pressure in lung transplant recipients: a single-institution experience.

Authors:  Chi Young Kim; Ji Eun Park; Ah Young Leem; Joo Han Song; Song Yee Kim; Kyung Soo Chung; Eun Young Kim; Ji Ye Jung; Young Ae Kang; Young Sam Kim; Joon Chang; Jin Gu Lee; Hyo Chae Paik; Moo Suk Park
Journal:  J Thorac Dis       Date:  2018-03       Impact factor: 2.895

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.